MANAGEMENT OF THE OLDER PATIENT WITH GLIOBLASTOMA IN THE UK: AN INITIAL REPORT FROM THE HISTO-MOL GBM COLLABORATIVE
Stephen Robinson,Katherine Ryan,Louisa Black,Sam Forner,Nathaniel Luke Hatton,Rebecca Hatton,Nurjahan Aktar,Haydn Lathangue,David Conkey,Praveen Durage,Paolo de Luna,Pavlos Christodoulou,Timothy Hill,Rachel MacArthur,May Teoh,Adenike Williams,Jennifer Golten,Tasia Aghadiuno,Kohgulakuhan Yogalingam,Jennifer Kahan,Sanjay Dixit,Samir Guglani,Rachel Lewis,Rafael Moleron,Najmus Iqbal,Nick Wadd,Prashanth Bhat,Georgios Giamas,Nektarios Mazarakis,Cressida Lorimer,Edward Chandy,Giles Critchley,Dr Stephen Robinson,Dr Katherine Ryan,Dr Louisa Black,Dr Sam Forner,Dr Nathaniel Luke Hatton,Dr Rebecca Hatton,Dr Nurjahan Aktar,Mr Haydn Lathangue,Dr David Conkey,Dr Praveen Durage,Mr Paolo de Luna,Dr Pavlos Christodoulou,Dr Timothy Hill,Ms Rachel MacArthur,Dr May Teoh,Dr Adenike Williams,Dr Jennifer Golten,Dr Tasia Aghadiuno,Dr Kohgulakuhan Yogalingam,Dr Jennifer Kahan,Dr Sanjay Dixit,Dr Samir Guglani,Dr Rachel Lewis,Dr Rafael Moleron,Dr Najmus Iqbal,Dr Nick Wadd,Dr Prashanth Bhat,Prof Georgios Giamas,Dr Nektarios Mazarakis,Dr Cressida Lorimer,Dr Edward Chandy,Prof Giles Critchley
DOI: https://doi.org/10.1093/neuonc/noae158.019
2024-10-01
Neuro-Oncology
Abstract:Abstract AIMS The management of older (>70 years old) patients with glioblastoma is challenging with significant variation in practice. Using the Histo-Mol GBM database we analysed the variation in practice across 11 UK centres. METHOD Biopsy confirmed glioblastoma patients diagnosed between 01/01-31/12/2021 were identified. Descriptive statistics were used to compare demographic, tumour and treatment characteristics, and the Kaplan-Meier method was used to analyse survival, assessed from surgery date. Differences in treatment between centres were assessed using one way ANOVA. RESULTS In 2021, 81/330 (24.5%) patients with glioblastoma were >70. Compared to younger patients, the older cohort had a greater proportion of males (79.0% vs 59.0%, p<0.001), a worse performance status (66.7% vs 79.5% ECOG PS 0-1, p<0.001), and more likely to have MGMT promoter methylation (30.9% vs 22.9%, p=0.027). Most patients received biopsy only (31/81, 38.3%), followed by subtotal resection (85-94% tumour resection) (26/81, 32.1%), whilst 8/81 (9.9%) underwent debulking, 8/81 near-total resection (95-99% tumour resection), and 8/81 gross total resection, with statistically significant variation in resection extent between centres (p=0.031). Adjuvant radiotherapy was used in 56/81 patients (69.1%) with no difference between centres (p=0.220). However, there was a statistically significant difference in radiotherapy regime between centres (p=0.041). 6/81 (7.4%) received conventional chemoradiotherapy, 28/81 (34.6%) hypofractionated chemoradiotherapy, 16/81 (19.8%) hypofractionated radiotherapy alone, 2/81 (2.5%) temozolomide alone both with MGMT promoter methylation, and 21/81 (25.9%) received no oncological treatment. Median progression free survival was 5.9 months and median overall survival (OS) was 7.1 months with no difference between centres (p=0.199 and p=0.083 respectively). Median OS was 8.4 months with conventional fractionation chemoradiotherapy, 11.2 months with hypofractionated chemoradiotherapy, 7.3 months with hypofractionated radiotherapy alone, 1.8 months with temozolomide alone, and 2.5 months with no oncological treatment. CONCLUSION We identify variations in the treatment of elderly glioblastoma patients across the UK, although these do not significantly impact survival.
oncology,clinical neurology